both increase serotonin levels. Modify Therapy/Monitor Closely.apomorphineapomorphine and lithium both increase QTc interval. Use Caution/Monitor.arformoterolarformoterol and lithium both increase QTc interval. Use Caution/Monitor.aripiprazolelithium, aripiprazole. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).aripiprazole and lithium both increase QTc interval. Use Caution/Monitor.asenapinelithium, asenapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).aspirinaspirin increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.aspirin rectalaspirin rectal increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.aspirin/citric acid/sodium bicarbonateaspirin/citric acid/sodium bicarbonate increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.atomoxetineatomoxetine and lithium both increase QTc interval. Use Caution/Monitor.benazeprilbenazepril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule. Monitor lithium levels.bendroflumethiazidebendroflumethiazide increases toxicity of lithium by decreasing elimination. Use Caution/Monitor.bexagliflozinbexagliflozin decreases effects of lithium by Other (see comment). Use Caution/Monitor. Comment: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes.buspironebuspirone and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.canagliflozincanagliflozin decreases levels of lithium by Other (see comment). Use Caution/Monitor. Comment: SGLT2 inhibitors with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes.captoprilcaptopril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule. Monitor lithium levels.carbamazepinecarbamazepine, lithium. Mechanism: unknown. Use Caution/Monitor. Risk of neurotoxicity.cariprazinelithium, cariprazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).celecoxibcelecoxib increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.chlorothiazidechlorothiazide increases toxicity of lithium by decreasing elimination. Use Caution/Monitor.chlorpromazinelithium, chlorpromazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.chlorthalidonechlorthalidone increases toxicity of lithium by decreasing elimination. Use Caution/Monitor.choline magnesium trisalicylatecholine magnesium trisalicylate increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.ciprofloxacinlithium and ciprofloxacin both increase QTc interval. Use Caution/Monitor.citalopramcitalopram, lithium. Mechanism: unknown. Use Caution/Monitor. Lithium may enhance the serotonergic effects of citalopram, caution should be exercised when citalopram and lithium are coadministered.clomipramineclomipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and clomipramine both increase QTc interval. Use Caution/Monitor.clozapinelithium, clozapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).cocaine topicalcocaine topical and lithium both increase serotonin levels. Use Caution/Monitor.cyclopenthiazidecyclopenthiazide increases toxicity of lithium by decreasing elimination. Use Caution/Monitor.dapagliflozindapagliflozin decreases levels of lithium by Other (see comment). Use Caution/Monitor. Comment: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes.daridorexantlithium and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. dasatinibdasatinib and lithium both increase QTc interval. Use Caution/Monitor.degarelixdegarelix and lithium both increase QTc interval. Use Caution/Monitor.desipraminedesipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and desipramine both increase QTc interval. Use Caution/Monitor.deutetrabenazinedeutetrabenazine and lithium both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexfenfluraminedexfenfluramine and lithium both increase serotonin levels. Use Caution/Monitor.dextroamphetaminedextroamphetamine and lithium both increase serotonin levels. Use Caution/Monitor.dextroamphetamine transdermallithium, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).dextromethorphandextromethorphan and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.diclofenacdiclofenac increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.difelikefalindifelikefalin and lithium both increase sedation. Use Caution/Monitor.diflunisaldiflunisal increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.dihydroergotaminedihydroergotamine and lithium both increase serotonin levels. Use Caution/Monitor.dihydroergotamine intranasaldihydroergotamine intranasal and lithium both increase serotonin levels. Use Caution/Monitor.diltiazemdiltiazem increases toxicity of lithium by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of neurotoxicity.dolasetrondolasetron and lithium both increase QTc interval. Use Caution/Monitor.doxepindoxepin and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.doxepin and lithium both increase QTc interval. Use Caution/Monitor.dulaglutidedulaglutide, lithium. Other (see comment). Use Caution/Monitor. Comment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index.duloxetineduloxetine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.efavirenzefavirenz and lithium both increase QTc interval. Use Caution/Monitor.eletriptaneletriptan and lithium both increase serotonin levels. Use Caution/Monitor.empagliflozinempagliflozin decreases levels of lithium by Other (see comment). Use Caution/Monitor. Comment: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes.enalaprilenalapril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.ergotamineergotamine and lithium both increase serotonin levels. Use Caution/Monitor.ertugliflozinertugliflozin decreases levels of lithium by Other (see comment). Use Caution/Monitor. Comment: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes.escitalopramescitalopram and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and escitalopram both increase QTc interval. Use Caution/Monitor.etodolacetodolac increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.fenfluraminefenfluramine and lithium both increase serotonin levels. Use Caution/Monitor.fenoprofenfenoprofen increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.ferric maltolferric maltol, lithium. Either increases levels of the other by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Coadministration of ferric maltol with certain oral medications may decrease the bioavailability of either ferric maltol and some oral drugs. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate administration of ferric maltol from these drugs. Duration of separation may depend on the absorption of the medication concomitantly administered (eg, time to peak concentration, whether the drug is an immediate or extended release product).fingolimodfingolimod and lithium both increase QTc interval. Use Caution/Monitor.fluconazolelithium and fluconazole both increase QTc interval. Use Caution/Monitor.fluoxetinefluoxetine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and fluoxetine both increase QTc interval. Use Caution/Monitor.fluphenazinelithium, fluphenazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.lithium, fluphenazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).lithium and fluphenazine both increase QTc interval. Use Caution/Monitor.flurbiprofenflurbiprofen increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.fluvoxaminefluvoxamine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and fluvoxamine both increase QTc interval. Use Caution/Monitor.fosinoprilfosinopril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.fostemsavirlithium and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. frovatriptanfrovatriptan and lithium both increase serotonin levels. Use Caution/Monitor.gemifloxacingemifloxacin and lithium both increase QTc interval. Use Caution/Monitor.gemtuzumablithium and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and lithium both increase QTc interval. Use Caution/Monitor.granisetrongranisetron and lithium both increase QTc interval. Use Caution/Monitor.haloperidollithium, haloperidol. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.lithium, haloperidol. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).lithium and haloperidol both increase QTc interval. Use Caution/Monitor.histrelinlithium and histrelin both increase QTc interval. Use Caution/Monitor.hydrochlorothiazidehydrochlorothiazide increases toxicity of lithium by decreasing elimination. Use Caution/Monitor.hydroxyzinehydroxyzine and lithium both increase QTc interval. Use Caution/Monitor.ibuprofenibuprofen increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.ibuprofen IVibuprofen IV increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.iloperidonelithium, iloperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).imidaprilimidapril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.imipramineimipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and imipramine both increase QTc interval. Use Caution/Monitor.indapamideindapamide increases toxicity of lithium by decreasing elimination. Use Caution/Monitor.lithium and indapamide both increase QTc interval. Use Caution/Monitor.indomethacinindomethacin increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.insulin aspartlithium, insulin aspart. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin aspart protamine/insulin aspartlithium, insulin aspart protamine/insulin aspart. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin degludeclithium, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. Comment: Lithium may either increase or decrease the blood glucose lowering effect of antidiabetic agents.lithium, insulin degludec. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin degludec/insulin aspartlithium, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. Comment: Lithium may either increase or decrease the blood glucose lowering effect of antidiabetic agents.insulin detemirlithium, insulin detemir. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin glarginelithium, insulin glargine. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin glulisinelithium, insulin glulisine. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin inhaledlithium, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. Comment: Lithium may either increase or decrease the blood glucose lowering effect of antidiabetic agents.lithium, insulin inhaled. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin isophane human/insulin regular humanlithium, insulin isophane human/insulin regular human. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin lisprolithium, insulin lispro. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin lispro protamine/insulin lisprolithium, insulin lispro protamine/insulin lispro. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin NPHlithium, insulin NPH. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.insulin regular humanlithium, insulin regular human. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin